Primecap Management Co. CA Reduces Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Primecap Management Co. CA lessened its stake in shares of Repligen Co. (NASDAQ:RGEN) by 43.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 30,858 shares of the biotechnology company’s stock after selling 23,871 shares during the quarter. Primecap Management Co. CA’s holdings in Repligen were worth $4,442,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of RGEN. Ballentine Partners LLC raised its stake in Repligen by 4.0% during the 4th quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company’s stock worth $270,000 after acquiring an additional 72 shares in the last quarter. CIBC Asset Management Inc grew its holdings in shares of Repligen by 5.0% during the fourth quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company’s stock worth $246,000 after purchasing an additional 81 shares during the last quarter. MML Investors Services LLC increased its position in shares of Repligen by 2.7% during the third quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock worth $503,000 after purchasing an additional 89 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Repligen by 15.2% in the 4th quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 90 shares during the last quarter. Finally, Louisiana State Employees Retirement System boosted its position in shares of Repligen by 0.7% in the 4th quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company’s stock valued at $2,087,000 after purchasing an additional 100 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Stock Up 0.4 %

Repligen stock opened at $144.88 on Thursday. The stock’s 50 day moving average price is $156.78 and its 200 day moving average price is $148.46. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $200.23. The company has a market cap of $8.12 billion, a PE ratio of -284.08, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The company had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. On average, sell-side analysts predict that Repligen Co. will post 1.72 EPS for the current fiscal year.

Analysts Set New Price Targets

RGEN has been the subject of a number of research reports. JPMorgan Chase & Co. boosted their price objective on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. Canaccord Genuity Group upped their price target on shares of Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research report on Friday, February 21st. Royal Bank of Canada lifted their price objective on shares of Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research note on Friday, February 21st. HC Wainwright reiterated a “buy” rating and set a $180.00 target price on shares of Repligen in a research note on Friday, February 21st. Finally, StockNews.com cut Repligen from a “hold” rating to a “sell” rating in a research report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $178.64.

Insider Buying and Selling at Repligen

In other news, Director Margaret Pax purchased 250 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were acquired at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the acquisition, the director now directly owns 1,043 shares in the company, valued at approximately $157,169.67. The trade was a 31.53 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.20% of the stock is currently owned by corporate insiders.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.